Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker

Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large numb...

Descripción completa

Detalles Bibliográficos
Autores principales: Signorelli, Diego, Giannatempo, Patrizia, Grazia, Giulia, Aiello, Marco Maria, Bertolini, Federica, Mirabile, Aurora, Buti, Sebastiano, Vasile, Enrico, Scotti, Vieri, Pisapia, Pasquale, Cona, Maria Silvia, Rolfo, Christian, Malapelle, Umberto, Group, Immune-Oncology YOUNG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/
https://www.ncbi.nlm.nih.gov/pubmed/31179334
http://dx.doi.org/10.1155/2019/9056417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507101/
https://www.ncbi.nlm.nih.gov/pubmed/31179334
http://dx.doi.org/10.1155/2019/9056417

Ejemplares similares